Scientific Programme

The detailed programme of the IIGANN Prague 2025 Symposium is available for download as a PDF file (12 MB) here.

DAY 1
17 September 2025
(Wednesday)

DAY 2
18 September 2025
(Thursday)

DAY 3
19 September 2025
(Friday)

DAY 4
20 September 2025
(Saturday)


07:55–08:55 Cubex A1 + A2	Breakfast & INDUSTRY SYMPOSIUM

09:00–10:00 Cubex A1 + A2	PANEL DISCUSSION: How do we ensure treatments are available to everyone with IgAN? Moderators: Heather Reich, Hernan Trimarchi Panellists: Irene de Lourdes Noronha, Vivekanand Jha, Adrian Liew, Bonnie Schneider

10:00–11:00 Cubex A1 + A2	PLENARY SESSION 4: IgAN Pathogenesis 2 Chairs: Renato Monteiro, Xueqing Yu Katherine Bull: Understanding the glomerular response to IgA deposition Heather Reich: Immune cells in the kidney are they important in IgAN? Dana Rizk: The role of complement in IgAN (the glomerulus and beyond)

11:00–11:30	Coffee break

11:30–11:50 Cubex A1 + A2	PLENARY SESSION 5: IIGANN Research Group Lecture 2 Chair: Mark Haas Peter Boor: Pathomics and next generation pathology in IgAN and IgAVN

11:50–13:00 Cubex A1 + A2	FREE COMMUNICATIONS Chair: Mark Haas Fabio Sallustio: Renal Progenitor Cells Can Modulate Inflammatory and Intestinal Immune Activation in IgA Nephropathy Ying Zheng: CX3CR1+ monocytes/macrophages promote regional immune injury in mesangial proliferative glomerulonephritis through crosstalk with activated mesangial cells Yuko Makita: Transglutaminase-2 specific IgA-producing plasma cells in experimental IgA nephropathy Selvin Sundar Raj Mani: Gut Microbiome in IgA Nephropathy: Associations with Baseline Disease Presentation and Longitudinal Clinical Outcomes in South Asians Yoshihito Nihei: Mucosal bacteria initiate production of anti-β2-spectrin IgA autoantibody through a mechanism of molecular mimicry Francesca Zanoni: Polygenic Risk Score Predicts IgA Nephropathy Recurrence and Graft Failure in Kidney Transplant Recipients Fabio Sallustio: MBL2 Deficiency and Graft Survival in Transplant Patients with IgA Nephropathy: Is Complement Inhibition Always Beneficial?

13:00–14:00 Cubex A1 + A2	Lunch & INDUSTRY SYMPOSIUM

14:00–15:00 Cubex A1 + A2	PLENARY SESSION 6: Treatment 1 Chairs: Daniel Cattran, Vladimir Tesar Jürgen Floege: What do the KDIGO Guidelines NOT tell us? Richard Lafayette: Who should we treat? Sydney Chi Wai Tang: How best to manage CKD in IgAN?

15:00–15:30 Cubex A1 + A2	FREE COMMUNICATIONS Chairs: Daniel Cattran, Vladimir Tesar Linlin Xu: Unveiling Genetic Determinants of Steroid Responsiveness in IgA Nephropathy: A TESTING Cohort Study David L. Hölscher: Pathomics-based estimation of treatment effects for corticosteroids in IgAN Xujie Zhou: Genome-wide association study meta-analysis reveals 50 susceptibility loci for IgA nephropathy and identifies B-cell receptor signaling to NF-κB pathway as a potential therapeutic target

15:30–16:00	Coffee break

16:00–17:00 Cubex A3	MODERATED POSTER SESSION Moderator: Kerstin Ebefors MP-01 Meijun Si: Revealing the Spatial Structure of IgA Immune Complexes in IgA Nephropathy Using Volume Electron Microscopy MP-02 Stacy D. Hall: Complement C3: A necessary component of pathogenic IgA1-containing immune complexes in IgA nephropathy MP-03 Zhenhai Zhang: Functional characterization of a novel anti-Gd-IgA1 autoantibody P4 in IgA nephropathy pathogenesis MP-04 Tibor Schomber: Effects of anti-APRIL antibody treatment versus dual APRIL/BAFF inhibition and anti-BAFF antibody treatment in wild type mice MP-05 Jan Novak: In vivo evidence that mesangioproliferative activity of IgA1-IgG immune complexes in IgA nephropathy requires complement C3 and can be prevented by a protein tyrosine kinase inhibitor MP-06 Colin Reily: NF-kB inhibitor increases production of galactose-deficient IgA1 and modulates activation of multiple transcription factors in several subpopulations of EBV-immortalized B cells from IgAN patients and healthy controls MP-07 Chee Kay Cheung: Urinary biomarker analysis reveals rapid intrarenal anti-inflammatory and anti-fibrotic effects of sparsentan in IgA nephropathy in the SPARTAN study MP-08 Jicheng Lv: PEGylated Clostridium ramosum IgA protease clears both circulating and deposited IgA1 as a potential disease-modifying therapy for IgA nephropathy MP-09 Kazuaki Mori: Sparsentan decreases mesangial IgA deposition in gddY mice; a possible role for mesangial-cell- surface autoantigen expression MP-10 Kerstin Ebefors: Activation of mesangial cells via phagocytosis in IgA nephropathy Moderator: Yuko Makita MP-11 Alexandra Audemard-Verger: Recommendations on diagnosis and treatment of adult-onset IgA Vasculitis proposed by the European IgA Vasculitis Study Group: focus on kidney involvement MP-12 Zhiqiang Du: Preclinical and phase I clinical study of RG002C0106: a GalNAc-siRNA conjugate for complement-related glomerular diseases MP-13 Federica Papadia: Epidemiological and Prognostic Insights into IgA Nephropathy: A Regional Cohort Study from Southern Italy MP-14 Selvin Sundar Raj Mani: Baseline and Longitudinal Associations between serum C3/C4 levels and tissue complement biomarkers and IgA Nephropathy in South Asia MP-15 Nobuo Tsuboi: Prognostic Significance of Persistent Hematuria in Japanese Patients with IgA Nephropathy: Findings from the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) MP-16 Hiroyuki Ueda: Prognostic impact of proteinuria recurrence in IgA nephropathy: A post hoc analysis of the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) MP-17 Shinya Yokote: Prognosis of Elderly Patients with IgA Nephropathy: A Post Hoc Analysis of the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) MP-18 Dita Maixnerova: Intercontinental survey of patients with IgA nephropathy – preliminary analysis MP-19 Keiichi Matsuzaki: Clinical Remission in IgA Nephropathy: Visualization of transition patterns and identification of an appropriate time point for prognostic assessment Moderator: Matthew B. Renfrow MP-20 Eyal Rahmani: Long-Term Outcomes in IgA Nephropathy: Findings from the ERKNet Patient Registry (ERKReg) MP-21 Benedetta De Ponte Conti: Investigation of gut-derived immune cell in IgA nephropathy MP-22 Fengtao Cai: Proteomics Unveils Molecular Profiles and Potential Pathogenic Mechanisms in IgA Nephropathy MP-23 Jacqueline Haller: Association of Urinary Inflammatory Biomarkers with Disease Activity and Progression Risk in IgAN and IgAVN: Findings from a Single-Center Cohort MP-24 Joshua Strzalka: Soluble Fcγ receptor ectodomains as inhibitors of FcγR activation in immune complex-mediated diseases MP-25 Karin Bergen: Lower urine epidermal growth factor to monocyte chemoattractant protein 1 ratio is associated with elevated biomarkers of endothelial dysfunction in IgA nephropathy MP-26 Karin Bergen: Plasma endothelial biomarkers in relation to albuminuria, kidney function and CKD progression in IgA-nephropathy (encore from 62nd ERA congress) MP-27 Yudai Tsuji: Comparative proteomic analysis of glomeruli and circulating IgA-immune complexes in IgA nephropathy MP-28 Kirk J. Rowley: Targeting APRIL and BAFF pathways: Divergent effects on immune populations and protective immunity, with implications for IgAN management Moderator: Xu-jie Zhou MP-29 Shu Qu: Genetic regulation and therapeutic targeting of MTMR3 reshape TLR9-mediated IgA responses MP-30 Sho Hamaguchi: Deep shotgun metagenomic analysis of the oral microbiome identifies extrachromosomal mobile genetic elements associated with IgA nephropathy MP-31 Cheng-Hsu Chen: The Genetic Study Identifies Susceptibility Loci for IgA Nephropathy MP-32 Francesca Annese: Molecular endophenotyping of IgA Nephropathy patients reveals immune-driven subgroups with distinct clinical outcomes MP-33 Amandine Badie: The role of sCD89 myeloid receptor in glomerular hypercellularity in childhood IgA nephropathy MP-34 Ming Li: The effects of multi-locus interaction on IgA nephropathy in Han Chinese population MP-35 Filippo Azzali: Engineering of IgA-specific CARs for CAR-T cell therapy against IgA nephropathy MP-36 Connor Hebborn: Evaluation of inhibitory oligotherapy for modulation of IgA expression MP-37 Mayuko Kawabe: Tonsillar Immune Signatures in IgA Nephropathy: Elevated KLRG1 and ZBTB16 Expression in Germinal Center Regions MP-38 Xu-jie Zhou: Causal Relationships Between Gut Microbiota and IgA Nephropathy: Evidence from Mendelian Randomization and Microbiome Validation

18:00–22:00	Conference Dinner

Last update on 3 September 2025.

The programme might be subject to necessary changes.